Weekly Investment Analysts’ Ratings Changes for Celldex Therapeutics (CLDX)

Several analysts have recently updated their ratings and price targets for Celldex Therapeutics (NASDAQ: CLDX):

• 5/9/2025 – Celldex Therapeutics had its price target lowered by analysts at Morgan Stanley from $46.00 to $43.00. They now have an “overweight” rating on the stock.
• 5/9/2025 – Celldex Therapeutics had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $36.00 to $31.00. They now have a “neutral” rating on the stock.
• 5/9/2025 – Celldex Therapeutics had its price target lowered by analysts at UBS Group AG from $44.00 to $38.00. They now have a “buy” rating on the stock.
• 5/6/2025 – Celldex Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
• 4/28/2025 – Celldex Therapeutics is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $64.00 price target on the stock.
• 3/20/2025 – Celldex Therapeutics is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $46.00 price target on the stock.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock opened at $19.62 on Wednesday. Celldex Therapeutics, Inc. has a 1 year low of $14.40 and a 1 year high of $47.00. The firm has a 50 day moving average price of $18.93 and a 200 day moving average price of $22.73. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -7.63 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The company had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. Sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its holdings in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 878 shares during the period. GAMMA Investing LLC grew its stake in Celldex Therapeutics by 6,665.9% during the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 2,933 shares during the period. Headlands Technologies LLC purchased a new position in shares of Celldex Therapeutics in the 4th quarter valued at $81,000. KBC Group NV lifted its holdings in shares of Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 1,647 shares in the last quarter. Finally, AlphaQuest LLC boosted its position in Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,705 shares during the period.

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.